Amgen Inc. is focusing on its weight-loss drug MariTide, which could potentially generate up to $3.7 billion in sales by 2030, contingent on receiving regulatory approval within the next three years. Despite the setback of halting clinical trials for rocatinlimab due to safety concerns, Amgen is reallocating R&D funds toward promising therapies such as obesity and oncology treatments. The company continues to attract investor interest with a robust quarterly dividend of $2.52 per share, even as it anticipates accelerated sales erosion from established products due to increasing biosimilar competition.
“Amgen doesn't have an approved weight loss medicine yet. However, it has made progress with its leading candidate, MariTide, which is now in phase 3 studies. The drug is being investigated in several different areas, including weight management, obstructive sleep apnea (OSA) treatment, and effects on cardiovascular outcomes. MariTide could earn approval within the next three years, provided it performs well in ongoing studies.”
“According to some estimates, MariTide could generate $3.7 billion in sales by 2030, potentially making Amgen a non-trivial player in this market.”
“By contrast, Amgen's portfolio is more diversified. The company may succeed in joining this lucrative market in the next few years, but even if it doesn't, it should recover pretty quickly. In other words, Amgen can provide exposure to the weight-loss market, but with limited downside if it doesn't perform as well in this space as expected.”
“However, Amgen doesn't have an approved weight loss medicine yet. However, it has made progress with its leading candidate, MariTide, which is now in phase 3 studies.”
“According to some estimates, MariTide could generate $3.7 billion in sales by 2030, potentially making Amgen a non-trivial player in this market.”
“By contrast, Amgen's portfolio is more diversified. The company may succeed in joining this lucrative market in the next few years.”
“In other words, Amgen can provide exposure to the weight-loss market, but with limited downside if it doesn't perform as well in this space as expected.”
“The move lower in the Dow pulled a range of shares downward, with most of the Dow's blue-chip components in retreat. ... Amgen (AMGN) ... each dropped more than 3%.”
“Amgen Inc. (AMGN) Completes Phase 3 Trial for ABP 206 Opdivo Biosimilar Candidate. The trial enrolled 256 subjects with resected stage III or IV melanoma to demonstrate pharmacokinetic similarity and clinical efficacy over a 12-month adjuvant period.”
“If successful, ABP 206 could establish Amgen Inc. (NASDAQ:AMGN) as a key provider of lower-cost immunotherapy for advanced melanoma.”
“On February 19, 2026, Wells Fargo raised the price target on Amgen Inc. (NASDAQ:AMGN) from $325 to $375 while maintaining an Equal Weight rating.”
“Amgen (NASDAQ:AMGN) will present at the Leerink Partners 2026 Global Healthcare Conference at 9:20 a.m. ET on Wednesday, March 11, 2026. Peter Griffith, executive vice president and chief financial officer at Amgen, and Jasper van Grunsven, senior vice president of rare disease at Amgen, will participate in a fireside chat at the conference.”